TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.3, ss.206-212, 2015 (SCI-Expanded)
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39.